A new experimental vaccine targeting the three most common deadly fungal infections has shown promising results in animal studies, potentially opening the door to human trials for a disease category that kills an estimated 1.6 million people every year. The vaccine, developed by researchers at the University of Georgia, is the first of its kind to take aim at all three major fungal threats in a single shot.
At a glance
- Pan-fungal vaccine: The experimental vaccine, called NXT-2, targets Aspergillus, Candida, and Pneumocystis — the three genera responsible for the vast majority of deadly fungal infections in humans.
- Preclinical results: In multiple animal models, NXT-2 induced broad, cross-reactive antibody responses and reduced both illness and death in immunosuppressed animals exposed to all three pathogens.
- Fungal disease burden: The World Health Organization released its first-ever Fungal Priority Pathogens list in 2022 C.E., flagging invasive fungal infections as a serious and growing public health threat with few effective treatments.
Why fungal infections have been so hard to fight
Most fungi cannot survive at human body temperatures, but a handful of species thrive in the warmth of our bodies. Researchers discovered about a decade ago that dozens of fungal species live inside us as part of what is now called the mycobiome. For healthy people, most are harmless. For those who are immunocompromised — due to HIV, cancer treatment, organ transplants, or other conditions — they can be fatal.
The three most dangerous genera are Aspergillus, which attacks the lungs and can spread through the bloodstream; Candida, a yeast that causes serious systemic infections; and Pneumocystis, which triggers a severe form of pneumonia in people with weakened immune systems. Together they account for the overwhelming majority of deaths from invasive fungal disease.
Anti-fungal medications exist, but the options are limited, and fungal resistance to these drugs is rising. No approved vaccine has ever existed for any of these pathogens — until now, researchers believe they may have a viable candidate.
What the new research found
The study, published in the journal PNAS Nexus, tested NXT-2 across several animal models. The recombinant peptide vaccine worked by training the immune system to recognize proteins shared across the three fungal genera, producing what the researchers describe as broad, cross-reactive antibody responses.
Critically, the vaccine reduced morbidity and mortality in immunosuppressed animals — the very population most at risk. That finding matters because vaccines often perform well in healthy immune systems but struggle in compromised ones.
“There’s a significant unmet clinical need for this kind of prevention and also treatment, particularly among immunocompromised individuals,” said Karen Norris, the lead investigator on the study. “The patient population at risk for invasive fungal infections has increased significantly over the last several years.”
A long-neglected public health threat
The scale of the problem is hard to overstate. The WHO’s 2022 C.E. Fungal Priority Pathogens list was the organization’s first formal acknowledgment that fungi represent an emerging global health emergency. Yet the research investment in fungal disease has lagged far behind that directed at bacterial or viral pathogens.
Justin Beardsley, an infectious disease researcher from the University of Sydney who worked with the WHO on the 2022 C.E. list, has called fungi the “forgotten infectious disease.” He has argued they cause devastating illness but have been neglected so long that scientists barely understand the true size of the problem.
That neglect has real consequences. People living with HIV, those undergoing chemotherapy, and organ transplant recipients all face significantly elevated risk, and in low- and middle-income countries where diagnostic capacity is limited, many infections go undetected and untreated.
What comes next
The University of Georgia team is clear that more work remains before human trials can begin. Researchers still need to establish optimal formulations and doses, and safety data will need to meet regulatory standards before any preliminary human testing is authorized. The path from promising animal data to an approved vaccine is long and often unpredictable — many candidates that perform well in animal models do not survive the rigors of human trials.
Still, the field now has a genuine candidate where none existed before. University of Georgia researchers and their collaborators have shown that a single vaccine can provoke meaningful immune responses against three distinct fungal genera simultaneously — a scientific feat that had not been demonstrated previously in peer-reviewed research.
The global rise in immunocompromising conditions, combined with climate change expanding the geographic range of some dangerous fungi, means demand for effective prevention tools will only grow. The U.S. Centers for Disease Control and Prevention has flagged fungal disease as a priority area, and the WHO list has brought new international attention and, researchers hope, new funding to the field.
For the millions of people whose immune systems leave them vulnerable, a vaccine that works would be more than a medical advance. It would be a lifeline.
Read more
For more on this story, see: New Atlas
For more from Good News for Humankind, see:
- Alzheimer’s risk cut in half by drug in landmark prevention trial
- Indigenous land rights and COP30: 160 million hectares
- The Good News for Humankind archive on global health
About this article
- 🤖 This article is AI-generated, based on a framework created by Peter Schulte.
- 🌍 It aims to be inspirational but clear-eyed, accurate, and evidence-based, and grounded in care for the Earth, peace and belonging for all, and human evolution.
- 💬 Leave your notes and suggestions in the comments below — I will do my best to review and implement where appropriate.
- ✉️ One verified piece of good news, one insight from Antihero Project, every weekday morning. Subscribe free.
